13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001389933
Total reported value
$524.4M
$524.4M
83 檔
30.6%
In Q1 2026, DAFNA Capital Management LLC's U.S. equity holdings reached a combined market value of $524.4M, distributed across 83 disclosed stock positions.
DAFNA Capital Management LLC executed strategic sector rebalancing during Q1 2026, establishing 10 new positions while fully exiting 4 holdings and trimming 29 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 12.85% | +7.24% | -3.94% | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.25% | -3.32% | -5.35% | |
| 3 | STXS | Stereotaxis Inc | Stock-Other | 5.73% | -1.24% | — | |
| 4 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 4.77% | -4.77% | EXIT | |
| 5 | ATRC | Atricure Inc | Stock-Other | 3.88% | -0.69% | — | |
| 6 | IDYA | Ideaya Biosciences Inc | Stock-Other | 3.61% | -0.08% | -5.92% | |
| 7 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.32% | -0.43% | -12.91% | |
| 8 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.26% | -0.47% | -41.38% | |
| 9 | CMPS | Compass Pathways PLC | Stock-Other | 3.04% | +2.39% | +198.24% | |
| 10 | NKTR | Nektar Therapeutics | Stock-Other | 2.70% | +1.54% | +120.24% | |
| 11 | IBB | Ishares Biotechnology ETF | ETF-Tech | 2.39% | -0.85% | -8.81% | |
| 12 | RCUS | Arcus Biosciences Inc | Stock-Other | 2.18% | +0.42% | +2.90% | |
| 13 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.12% | -0.26% | — | |
| 14 | LRMR | Larimar Therapeutics Inc | Stock-Other | 2.08% | -0.91% | +116.06% | |
| 15 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.91% | -0.30% | +61.22% | |
| 16 | AXGN | Axogen Inc | Stock-Other | 1.88% | -0.04% | -47.58% | |
| 17 | BHVN | Biohaven Ltd. | Stock-Other | 1.63% | -1.24% | -11.46% | |
| 18 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.55% | -0.53% | — | |
| 19 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.39% | +2.23% | — | |
| 20 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | Bond | 1.35% | -1.35% | EXIT | |
| 21 | IPSC | Century Therapeutics Inc | Stock-Other | 1.25% | -0.13% | -12.86% | |
| 22 | DXCM | Dexcom Inc | Stock-Healthcare | 1.23% | -0.12% | -2.27% | |
| 23 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.22% | -1.22% | EXIT | |
| 24 | ASND | Ascendis Pharma A/S | Stock-Other | 1.21% | -1.21% | EXIT | |
| 25 | MBX | Mbx Biosciences Inc | Stock-Other | 1.19% | -1.07% | +6.17% | |
| 26 | INGN | Inogen Inc | Stock-Other | 1.19% | -0.15% | +2.19% | |
| 27 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.16% | +0.24% | -21.77% | |
| 28 | ALKS | Alkermes plc | Stock-Healthcare | 1.12% | -0.11% | +7.09% | |
| 29 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.97% | -0.15% | +20.21% | |
| 30 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.93% | -0.17% | +2.87% | |
| 31 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 0.89% | -0.15% | — | |
| 32 | IMVT | Immunovant Inc | Stock-Other | 0.85% | +0.25% | — | |
| 33 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.80% | +0.96% | -29.74% | |
| 34 | MPLT | Maplight Therapeutics Inc | Stock-Other | 0.79% | +0.38% | +18.95% | |
| 35 | ALLO | Allogene Therapeutics Inc | Stock-Other | 0.76% | +0.03% | -0.72% | |
| 36 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.68% | -0.16% | — | |
| 37 | ALGN | Align Technology Inc | Stock-Healthcare | 0.58% | -0.13% | -6.25% | |
| 38 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.58% | -0.04% | — | |
| 39 | HELP | Cybin Inc | Stock-Other | 0.54% | +0.11% | +9.53% | |
| 40 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.53% | +0.07% | — | |
| 41 | PODD | Insulet CORP | Stock-Healthcare | 0.52% | +1.28% | +58.22% | |
| 42 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.51% | -0.03% | +25.68% | |
| 43 | ✓ | Immatics NV | Stock-Other | 0.51% | -0.28% | -13.51% | |
| 44 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.49% | — | — | |
| 45 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.49% | -0.16% | +10.62% | |
| 46 | ALEC | Alector Inc | Stock-Other | 0.44% | -0.09% | — | |
| 47 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.44% | — | — | |
| 48 | KURA | Kura Oncology Inc | Stock-Other | 0.44% | -0.19% | — | |
| 49 | PROF | Profound Medical CORP | Stock-Other | 0.39% | -0.06% | -7.95% | |
| 50 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.36% | -0.36% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DAWNGBX | Day One Biopharmaceuticals I | +2.6% | -2.07% | Trim |
| 2 | NKTR | Nektar Therapeutics | +2% | +120.24% | Add |
| 3 | CMPS | Compass Pathways PLC | +1.7% | +198.24% | Add |
| 4 | RVMD | Revolution Medicines Inc | +1.7% | -3.94% | Trim |
| 5 | LRMR | Larimar Therapeutics Inc | +1.3% | +116.06% | Add |
| 6 | BCAX | Bicara Therapeutics Inc | +0.9% | +61.22% | Add |
| 7 | IPSC | Century Therapeutics Inc | +0.6% | -12.86% | Trim |
| 8 | XENE | Xenon Pharmaceuticals Inc | +0.3% | -12.91% | Trim |
| 9 | ALLO | Allogene Therapeutics Inc | +0.3% | -0.72% | Trim |
| 10 | ALKS | Alkermes plc | +0.3% | +7.09% | Add |
| 11 | MPLT | Maplight Therapeutics Inc | +0.2% | +18.95% | Add |
| 12 | RARE | Ultragenyx Pharmaceutical In | +0.2% | +281.88% | Add |
| 13 | DNLI | Denali Therapeutics Inc | +0.2% | — | Unchanged |
| 14 | BCRX | Biocryst Pharmaceuticals Inc | +0.2% | +2.87% | Add |
| 15 | STOK | Stoke Therapeutics Inc | +0.2% | +20.21% | Add |
| 16 | NGNE | Neurogene Inc | +0.1% | +102.46% | Add |
| 17 | ALEC | Alector Inc | +0.1% | — | Unchanged |
| 18 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | +0.1% | — | Unchanged |
| 19 | PODD | Insulet CORP | +0.1% | +58.22% | Add |
| 20 | CLDX | Celldex Therapeutics Inc | +0.1% | — | Unchanged |
| 21 | INSP | Inspire Medical Systems Inc | 0% | +111.63% | Add |
| 22 | ✓ | Compugen LTD | 0% | -5.37% | Trim |
| 23 | FATE | Fate Therapeutics Inc | 0% | — | Unchanged |
| 24 | ALGN | Align Technology Inc | — | -6.25% | Trim |
| 25 | RAPP | Rapport Therapeutics Inc | — | — | Unchanged |
| 26 | OBIO | Orchestra Biomed Holdings In | — | — | Unchanged |
| 27 | ✓ | Polypid LTD | — | — | Unchanged |
| 28 | ✓ | Adc Therapeutics SA | — | -6.49% | Trim |
| 29 | BNTX | Biontech Se-adr | 0% | — | Unchanged |
| 30 | AUTL | Autolus Therapeutics PLC | 0% | — | Unchanged |
| 31 | MBX | Mbx Biosciences Inc | 0% | +6.17% | Add |
| 32 | ACET | Adicet Bio Inc | 0% | — | Unchanged |
| 33 | KPTI | Karyopharm Therapeutics Inc | 0% | -10.20% | Trim |
| 34 | BCYC | Bicycle Therapeutics Plc-adr | 0% | — | Unchanged |
| 35 | FHTX | Foghorn Therapeutics Inc | 0% | -11.82% | Trim |
| 36 | IMVT | Immunovant Inc | 0% | — | Unchanged |
| 37 | ORIC | Oric Pharmaceuticals Inc | -0.1% | -30.01% | Trim |
| 38 | ✓ | Engene Holdings Inc | -0.1% | +14.49% | Add |
| 39 | VKTX | Viking Therapeutics Inc | -0.1% | — | Unchanged |
| 40 | MLYS | Mineralys Therapeutics Inc | -0.1% | — | Unchanged |
| 41 | GPCR | Structure Therapeutics Inc | -0.1% | +25.68% | Add |
| 42 | LKFT | Lakefront Biotherapeutic-adr | -0.1% | — | Unchanged |
| 43 | INGN | Inogen Inc | -0.1% | +2.19% | Add |
| 44 | ARAY | Accuray Inc | -0.1% | +20.42% | Add |
| 45 | EWTX | Edgewise Therapeutics Inc | -0.1% | -29.74% | Trim |
| 46 | 4XC1 | Kalvista Pharmaceuticals Inc | -0.1% | -25.06% | Trim |
| 47 | PROF | Profound Medical CORP | -0.1% | -7.95% | Trim |
| 48 | KURA | Kura Oncology Inc | -0.1% | — | Unchanged |
| 49 | ✓ | Immatics NV | -0.1% | -13.51% | Trim |
| 50 | DXCM | Dexcom Inc | -0.1% | -2.27% | Trim |
According to official SEC Form 13F filings, DAFNA Capital Management LLC reported a total U.S. public equity portfolio value of $524.4M across 83 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RVMD, XBI, STXS) accounted for 30.6% of total reported equity market value during Q1 2026.
Top New Position Initiated
FULC
市值: $1.6M
Top Position Liquidated / Trimmed
CATBUSD
前期市值: $4.0M
During Q1 2026, DAFNA Capital Management LLC's top holdings by market value included RVMD (12.8%)、XBI (9.3%)、STXS (5.7%). The largest single position, RVMD, represented 12.8% of total portfolio value.
In Q1 2026, DAFNA Capital Management LLC made 63 total portfolio adjustments, initiating 10 new buys, adding to 20 positions, trimming 29 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.